Back Pain News and Research

Latest Back Pain News and Research

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte Corporation announced today results from the global, pivotal Phase III clinical program of ruxolitinib in patients with myelofibrosis (MF) at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

6 Jun 2011

Delayed treatment could prove effective in certain medical conditions

In today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery store or for an Internet connection — is rarely considered a good thing.

3 Jun 2011

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

1 Jun 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Coronary artery disease is a leading cause of death in U.S. women

It's a silent killer, most women don't even know they have it. It's often thought of as a man's disease and may not receive as much attention as other illnesses, but coronary artery disease (CAD) is the leading cause of death in women in the U.S. It is so common that if you combine the number of women who die from the next five leading causes of death it would equal the number of women who die from CAD.

26 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Nerve stimulation device approved for pain

The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.

From Medtronic 24 May 2011

Stimulating electrode array assists paralyzed man to regain voluntary movements of limbs

A team of researchers from the University of California, Los Angeles (UCLA), the California Institute of Technology (Caltech), and the University of Louisville have used a stimulating electrode array to assist a paralyzed man to stand, step on a treadmill with assistance, and, over time, to regain voluntary movements of his limbs.

21 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

Complementary and alternative health practices show promise for management of pain

A variety of complementary and alternative health practices —including meditation and relaxation techniques, manual therapies such as massage and spinal manipulation, meditative exercise forms such as yoga, Tai Chi, and ancient health practices such as acupuncture—show promise for contributing to the management of pain according to research presented at the Annual Scientific Meeting of the American Pain Society, www.ampainsoc.org.

20 May 2011

Breakthrough injectable gel for treating degeneration of the intervertebral disc

Chronic lower back pain is a major problem for society - behind only headaches as the most common neurological ailment - and is frequently caused by degeneration of the intervertebral disc.

From The University of Manchester 20 May 2011

Online program helps people to manage chronic pain

There is good news for the 76 million Americans who experience chronic pain including migraine, back pain, fibromyalgia and arthritis. A new study reveals that an online, self-paced chronic pain management program reduces the physical and psychological burdens of this debilitating condition.

19 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Treatment of chronic low back pain can reverse abnormal brain activity and function

It likely comes as no surprise that low back pain is the most common form of chronic pain among adults. Lesser known is the fact that those withchronic pain also experience cognitive impairments and reduced gray matter in parts of the brain associated with pain processing and the emotional components of pain, like depression and anxiety.

18 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

Bedside screening tool can help diagnose acute aortic dissection

The most lethal and sudden cardiovascular event can be the toughest for doctors to diagnose. But a study by the University of Michigan Cardiovascular Center shows new guidelines are effective for determining who's most likely suffering from an aortic dissection, which is tearing in the lining of the body's largest blood vessel.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced that the Company's Zhibai Dihuang Pill and Ciwujia Tablet have been approved for sale as traditional Chinese medicine in Hong Kong by Chinese Medicine Council of Hong Kong.

10 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

Back Pain News and Research

Latest Back Pain News and Research

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Delayed treatment could prove effective in certain medical conditions

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

Coronary artery disease is a leading cause of death in U.S. women

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Nerve stimulation device approved for pain

Stimulating electrode array assists paralyzed man to regain voluntary movements of limbs

EMA CHMP recommends conditional marketing authorization of FAMPYRA

Complementary and alternative health practices show promise for management of pain

Breakthrough injectable gel for treating degeneration of the intervertebral disc

Online program helps people to manage chronic pain

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Treatment of chronic low back pain can reverse abnormal brain activity and function

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

Bedside screening tool can help diagnose acute aortic dissection

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Back Pain News and Research

Latest Back Pain News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in